MYOS Corporation Issues Letter to Shareholders Highlighting Key Accomplishments
CEDAR KNOLLS, NJ -- (Marketwired) -- 06/24/15 -- MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, today issued the following letter to shareholders from the Company's Board of Directors.
Dear MYOS Shareholders,
We are pleased to provide you with an update on the Company's recent progress and plans for what we expect will be an important and productive second half of 2015. Our recent launch of our Rē Muscle Health™ Series represents an important milestone in our history and reflects our strategy to exploit the momentum we've generated both commercially and through our clinical and basic research.
We believe we have built a strong product platform grounded in a natural, extremely safe, muscle-building ingredient, strong intellectual property, world class manufacturing, a lean and effective corporate operating infrastructure and an emerging expertise in small molecules which we believe affects a vitally important molecular signalling system, on a fraction of the invested capital many peer companies have consumed in their early histories. We believe the new Rē Muscle Health Series -- an amazing product line of Fortetropin-based products designed to rebuild, rejuvenate, and result in increased lean muscle -- will enable MYOS to generate revenue to help fuel the growth of our biotherapeutics division. With Rē Muscle Health, MYOS has the best tasting, clinically proven, non-GMO, all-natural supplements in the market today.
Our core values are centered on our deep understanding that muscle health and performance are essential for general health and wellness and are an important component in the management of any chronic illness. While our focus remains on the discovery and development of traditional biotherapeutic products, MYOS has catalyzed our developing business with the strong early performance of our first commercial product. MYOS' measurable success with MYO-X®, powered by Fortetropin®, has enabled us to build a novel bionutrition business which exploits the important myostatin regulatory system to help drive our growth.
We are committed to building a biotherapeutics business based on an asset which is a powerful, yet all-natural, regulator of myostatin activity, which can be sold as a dietary supplement and bionutrition ingredient today. We believe this is an unprecedented advantage over traditional early stage biotherapeutics companies, which could require tens or hundreds of millions of dollars and up to a decade of development to identify and validate a bioactive product. MYOS has used its bionutrition business to serve as a proving ground, which justifies both the molecular target focus, myostatin, and confirms the clinical importance of controlling that system and its considerable commercial potential.
In our partnership with Cloud Pharmaceuticals, we are making progress through the use of a proprietary inverse design platform by utilizing cloud-computing techniques to design and synthesize novel drugs with a high degree of specificity. MYOS is seeking to build a pipeline of small molecules that will target muscle related conditions and diseases such as sarcopenia and cachexia. Currently, we are synthesizing JAK3 inhibitors that will target the inflammatory pathways, which is an important component of muscle wasting conditions and diseases. Additionally, a strategy for formulating small molecules and peptides that targets the myostatin pathway is currently in process.
Since the beginning of 2015, MYOS has made significant progress on multiple fronts that we believe are essential to unlocking the full potential of the MYOS technology platform. Specifically, we have:
- Established Fortetropin's Mechanism of Action
- Demonstrated that Fortetropin imparts its muscle building activity by targeting three key Muscle Health Pathways
- Presented research at the Keystone Symposia's Conference on the Human Proteome
- Presented Mechanism of Action Data at the Experimental Biology Conference
- Announced the Rē Muscle Health Series Powered by Fortetropin
- Initiated a Clinical Study on Fortetropin Dose Response
- Launched a Marketing campaign for the Rē Muscle Health series
- Received Health Canada Approval for Fortetropin
- Published a Research Article demonstrating the Impact of Fertility on the Chicken Egg Yolk Proteome in a Peer-Reviewed Journal
MYOS plans to conduct further clinical studies on Fortetropin in order to expand its use for the treatment of muscle loss associated with aging and other chronic illnesses.
MYOS intends to position itself as a leader in muscle health and expects to:
- Strengthen the management team with key appointments and preeminent scientific advisors
- Raise additional capital for our business
- Continue enhancement and expansion of product manufacturing and supply chain relations
- Continue to build our intellectual property and patent portfolio
- Build Rē Muscle Health™ products into a global brand
MYOS plans to initiate the following clinical programs
- Further expand our understanding of Fortetropin's mechanism of action in a Rodent Model
- Impact of Fortetropin on Sarcopenia - Aging Rodent Model
- Identify and isolate pro-myogenic active moieties of Fortetropin and evaluate their activities in rodent models
- In-vivo evaluation of novel small molecules inhibitors of Myostatin
- Effect of Fortetropin on Recovery post Knee and Hip Replacement
- Effect of Fortetropin to Prevent Atrophy after Orthopedic Surgery
- Effect of Fortetropin in Management of age related muscle loss (sarcopenia)
Finally, we are pleased to announce that we will be launching a new Rē Muscle Health™ website that will more effectively reflect the unique and powerful activity of these products while creating a compelling marketing case for the revolutionary nature of the brand's focus. We believe the new Rē Muscle Health™ website will help our customers navigate seamlessly through the purchase process while allowing them to engage with the brand through social media.
On behalf of the MYOS Board and Management Team we would like to thank you for your unwavering support and we look forward to an exciting second half of 2015!
MYOS Board of Directors
About MYOS Corporation
MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin®, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com
About Rē Muscle Health™
The Rē Muscle Health™ series is the Company's first branded line of muscle health products. This unique line of all-natural, non-GMO products contain Fortetropin®, an egg-based, all-natural myostatin inhibitor clinically proven to build healthy muscle. The Rē Muscle Health™ series can be ordered by visiting www.remusclehealth.com. MYOS believes that Fortetropin®, as well as future products it envisions, will redefine existing standards for muscle health. The Rē Muscle Health™ product line is owned and sold directly by the Company at www.remusclehealth.com.
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin® and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, the successful launch and customer demand for our Rē Muscle Health™ and other products, the continued growth of repeat purchases, market acceptance of our existing and future products in countries outside of the United States (such as Canada), the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to collect our accounts receivable from our distributors, our ability to raise capital to fund continuing operations, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin® and Rē Muscle Health™, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.
MYOS Corporation Investor and Media Contact:
Source: MYOS Corporation
Released June 24, 2015